Healthcare Finance News January 14, 2025
Jeff Lagasse

Overall, these top 25 drugs were responsible for nearly $50 billion in total Medicare Part D spending in 2022, AARP finds.

The brand-name drugs covered under Medicare Part D have nearly doubled in price, and 25 of them are now up 98% since they debuted in the market, a new AARP Public Policy Institute analysis has found.

These lifetime price increases often greatly exceeded the corresponding rate of general inflation, AARP found.

The analysis also found that, on average, more than 40% of the current list prices for the top 25 drugs is due to price increases that have occurred since the products first entered the market.

All of the data was based on the 25 brand-name drugs with the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Insurance, Medicare, Pharma, Pharma / Biotech, Survey / Study, Trends
Value-based payment models: Doctors describe the disconnect between theory and practice
Nurse anesthetists outnumber anesthesiologists billing Medicare
OIG report finds just 40% of Medicare enrollees who started treatment for opioid use disorder continued
Fewer psychiatrists are billing Medicare: 5 things to know
Psychiatrists participating in Medicare Part B declines: Study

Share This Article